اختيار اللغة
وحدة البحوث الطبية العلاقات الثقافية شعبة ضمان الجودة و الأداء الجامعي وحدة التعليم الطبي و تطوير المناهج الدراسية لجنة التعضيد شعبة النشاطات الطلابية
  •  
  •  
  •  



Evaluation of CD 9 and CD 56 antigen expression in adult acute Myeloid Leukemia
صبح سالم عبد اللطيف
Authors : International Journal of advance Research
Background: -Acute myeloid leukaemia (AML) is a malignant clonal disorder resulting from the neoplastic proliferation of a clone of myeloid cells. Flow cytometry is used for confirming diagnosis, identifying prognostic differences, staging of AML and detecting an aberrant immunophenotype that can be used for monitoring of complete remission (CR) achievement. Objectives: - To evaluate the expression of aberrant CD9 and CD56 in newly diagnosed adult AML patients and their association with clinical and haematological parameters and with CR achievement. Methods: -Thirty adult patients (>15 years) who were newly diagnosed de novo AML were selected from the Baghdad Teaching Hospital andAl- ImameinKadhimein medical cityfrom July 2015 to March 2016. All patients were grouped according to FAB classification and evaluated individually and the diagnosis was based on the morphology, cytochemistry or flow cytometry. Aberrant antigens CD9 and CD56 expressions were investigated by four- colours flow cytometry at the time of diagnosis. The patients were evaluated at day 28 from the start of chemotherapy to assess complete remission achievement. Verbal consent was taken from the patients. Results: -The aberrant expression of CD56, CD9 were observed in 23.3% and 33.3% of AML patients respectively. CD56 was expressed more with monocytic differentiation and CD9 was expressed more with M2 cases. CD56 expression was significantly associated with high total WBC count, high peripheral blood and bone marrow blast cells and the extramedullary manifestations. There was significant association between CD56 and CD9 expression regardless of their intensity of the markers with non-responsiveness to induction therapy. Conclusion: -Aberrant CD9 and CD56 antigens were associated with adverse clinical and hematological parameters at presentation as well as with low cure rate.

(FULL ARTICLE LINK) Read more ...
) 2017